COVID symptoms, testing, shielding impact on patient‐reported outcomes and early vaccine responses in individuals with multiple myeloma

  1. Karthik Ramasamy
  2. Ross Sadler
  3. Sally Jeans
  4. Sherin Varghese
  5. Alison Turner
  6. Jemma Larham
  7. Nathanael Gray
  8. Joe Barrett
  9. Stella Bowcock
  10. Gordon Cook
  11. Chara Kyriakou
  12. Dean Smith
  13. Mark Drayson
  14. Supratik Basu
  15. Sally Moore
  16. Sarah McDonald
  17. Sarah Gooding
  18. Muhammad K. Javaid

Reviewed by

Read the full article

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1111/bjh.17764
  2. ScreenIT

    SciScore for 10.1101/2021.05.20.21257379: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsConsent: & RUDY LREC 17/SC/0501), an established online rare disease platform with online dynamic consent and patient reported outcome assessments8.
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    immunomodulatory drugs - thalidomide, lenalidomide, pomalidomide; CD38 antibody – daratumumab, Isatuximab; and others – Belantamab, bendamustine, cyclophosphamide, dexamethasone, other steroids.
    CD38
    suggested: None
    Serological testing: A serum sample was collected from each patient; this was tested for antibodies against SARS-CoV2 nucleocapsid (N) or spike (S) protein.
    SARS-CoV2 nucleocapsid (N
    suggested: None
    SARS-CoV2 N protein antibodies were measured by turbidimetry (Abbott), with samples that produced values of >1.4 considered to be positive.
    SARS-CoV2 N protein
    suggested: None
    SARS-CoV2 S protein antibodies were measured via 2 different methods; by turbidimetry (Abbott)(IgG serology only), with a cut-off value of 50 considered to be a positive result, and by ELISA (The Binding Site)(IgG, IgA, IgM serology as a combined result), where values greater than those for the calibrator sample were considered to be positive.
    SARS-CoV2 S protein
    suggested: (PhosphoSolutions Cat# CoV2-5G8, RRID:AB_2868396)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    Strengths and weaknesses of the study: Previous myeloma studies during the pandemic have primarily focussed on outcomes of COVID-19 infection in hospitalised myeloma patients. This is the first prospective study to report on history of COVID19 symptoms, testing, healthcare resource impact, and mental and social well being in the shielded population during both waves of the COVID-19 pandemic from a community based sample. This study highlights the effects of long term shielding / self -isolation, and changes in heathcare provision, have had on social and mental well being of myeloma patients. The effects are comparable to other cancer patients with incurable disease and require ongoing healthcare support13. The study was planned and recruitment started during the pandemic, which made the study exclusively online. This has biased the demographic to a relatively well, computer literate and younger cohort of patients The median age of the population is younger (62.9 yrs) than the typical median age at diagnosis (69 yrs) as computer literacy enables participation in this study. This may also have under represented the proportion of patients experiencing social isolation and either anxiety or depression. Details on chemotherapy were patient reported and therefore not fully captured through the online portal; and work is ongoing to record them from individual centres. Our study design does not capture the profoundly immunosuppressed MM patients who may have succumbed to SARS-CoV-2 i...

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2021.05.20.21257379v1 on medRxiv